Overview
Ashley Morales is an associate in our San Diego office. Her practice primarily focuses on patent litigation. She represents clients in a variety of technological areas and products, including pharmaceuticals, medical devices, and aesthetic and personal care products. Ashley also has experience litigating Hatch-Waxman, trademark, and breach of contract cases.
Ashley received her law degree from Columbia Law School, where she was Executive Editor for the Columbia Journal of Environmental Law. She received her bachelor’s degree in chemistry and political science from the University of Southern California.
Ashley joined the firm in 2015.
Education
- University of Southern California (USC) (B.A. Chemistry and Political Science, 2012), cum laude
- Columbia Law School (J.D., 2015)
Recognition
Awards & Honors
- Named a 2023 Rising Star in IP by Managing IP
News & Insights
Articles
Co-authored, Hatch-Waxman And Copying: An Exception To The Exception?, Law360 (November 2017)
Co-authored, Evidence Of Copying Is Irrelevant In Hatch-Waxman Cases, Law360 (September 2016)
Litigation Blog
- An Award of Attorneys’ Fees and Costs under 35 U.S.C. §285 Does Not Preclude Sanctions Pursuant to the Court’s Inherent Authority
- Federal Circuit Avoids Deciding Whether Statements to Foreign Patent Office Can Disavow U.S. Claim Scope
- Potential Claim Construction Error Is Harmless When Not Relied Upon by the Board
- Patent Term Adjustment Under 35 U.S.C. 154(b)(1)(C)(iii) Requires Reversal of Adverse Determination of Patentability
- Required Testing as Part of an Offer for Sale Does Not Preclude a Finding of a Commercial Sale for On-Sale Bar Defense
- Prosecution History Disclaimer and Estoppel Lead To Noninfringement
- Registration of a Multi-Color Mark Does Not Require Acquired Distinctiveness
- Single-Entity Requirement for Infringement Under § 271(a) Does Not Apply to § 271(g)
Biotechnology Blog
- Nobel Prize in Medicine Awarded to American Scientists for Discovery of microRNA
- Branded Manufacturers Decline to Remove Patents From the Orange Book After Receiving Letters From the FTC
- USPTO Issues Training Materials to Examiners for Searching FDA and NIH Resources
- The FDA Approves Two New Gene Therapies for the Treatment of Sickle Cell Disease
- Federal Circuit Revisits Standard for Enablement of Antibody Claims
- Federal Circuit Finds Patent for Dietary Supplements Invalid Under § 101 for Reciting Naturally Occurring Milk Components
Latest Updates and News
An Award of Attorneys’ Fees and Costs Under 35 U.S.C. §285 Does Not Preclude Sanctions Pursuant to the Court’s Inherent Authority
PS PRODUCTS INC. V. PANTHER TRADING CO. INC. Before Moore, Stoll, and Cunningham. Appeal from the Eastern District of Arkansas. Summary: Section 285 does not prohibit an award of deterrence...
Nobel Prize in Medicine Awarded to American Scientists for Discovery of microRNA
On October 7, 2024, the 2024 Nobel Prize in Physiology or Medicine was jointly awarded to two American scientists, Victor Ambros (of UMass Medical School) and Gary Ruvkun (of Harvard Medical School), for their discovery of microRNA, a new class of small noncoding RNA molecules, and the role microRNAs play in turning genes on and off, known as gene regulation.
Knobbe Martens, Over a Dozen Attorneys Recognized in Managing IP 2024 IP STARS Guide
IRVINE, Calif., October 10, 2024 – Knobbe Martens is proud to share that the firm and its partners have once again been recognized for outstanding intellectual property work by Managing...
Branded Manufacturers Decline to Remove Patents From the Orange Book After Receiving Letters From the FTC
On Friday, June 21, 2024, the FDA updated its Patent Listing Dispute List to indicate that the ten pharmaceutical companies who had received warning letters from the FTC in April did not make changes to their patent listings in the FDA’s catalog in view of the warning letters.
USPTO Issues Training Materials to Examiners for Searching FDA and NIH Resources
On March 20, 2024, The USPTO issued an alert, notifying practitioners that the USPTO had developed training materials for patent examiners regarding searching for prior art in FDA and NIH databases. The new training materials were presented to the public at the Biotechnology, Chemical, and Pharmaceutical Partnership Meeting, held in person at the USPTO headquarters in Alexandria, Virginia, and at the USPTO Silicon Valley Regional Office in San Jose, California, on March 19, 2020.
Federal Circuit Avoids Deciding Whether Statements to Foreign Patent Office Can Disavow U.S. Claim Scope
K-FEE SYSTEM GMBH v. NESPRESSO USA, INC.
Before Taranto, Clevenger, and Stoll. Appeal from the U.S. District Court for the Central District of California.
Summary: The Federal Circuit did not need to decide whether statements to the European Patent Office (EPO) can disavow claim scope in a U.S. patent because the statements in this case were too ambiguous to constitute disavowal.